Outcomes of anti-PD-L1 blockades plus etoposide and platinum (EP) as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC) with brain metastasis (BM).

被引：0
|
作者：
Tian, Yaru
Ma, Ji
Zhu, Hui
Yu, Jinming
机构：
[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China
[2] Peoples Hosp Leling, Dept Oncol, Leling, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20607
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.
    Chen, Yuanbin
    Paz-Ares, Luis G.
    Dvorkin, Mikhail
    Trukhin, Dmytro
    Reinmuth, Niels
    Chiara Garassino, Marina
    Statsenko, Galina
    Voitko, Oleksandr
    Hochmair, Maximilian
    Ozguroglu, Mustafa
    Verderame, Francesco
    Havel, Libor
    Losonczy, Gyorgy
    Conev, Nikolay
    Hotta, Katsuyuki
    Ji, Jun Ho
    Broadhurst, Helen
    Byrne, Natalie
    Thiyagarajah, Piruntha
    Wade Goldman, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Durvalumab ± tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.
    Paz-Ares, Luis G.
    Dvorkin, Mikhail
    Chen, Yuanbin
    Reinmuth, Niels
    Hotta, Katsuyuki
    Trukhin, Dmytro
    Statsenko, Galina
    Hochmair, Maximilian
    Ozguroglu, Mustafa
    Ji, Jun Ho
    Voitko, Oleksandr
    Poltoratskiy, Artem
    Verderame, Francesco
    Havel, Libor
    Bondarenko, Igor
    Armstrong, Jon
    Byrne, Natalie
    Jiang, Haiyi
    Goldman, Jonathan Wade
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
    Nadler, Eric S.
    Vasudevan, Anupama
    Davies, Kalatu
    Wang, Yunfei
    Johnson, Ann
    Ogale, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Durvalumab (D) ± tremelimumab (T) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES-SCLC): exploratory analysis of patients with long-term clinical benefit in CASPIAN
    Reinmuth, N.
    Paz-Ares, L. G.
    Panse, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 152 - 152
  • [35] First-line apatinib plus chemotherapy in extensive-stage small-cell lung cancer.
    Shi, Jian
    Liu, Jiayin
    Duan, Xiaoyang
    Huang, Guanglei
    Wang, Lixing
    Zhao, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report
    Xue, Lei
    Chen, Baishen
    Lin, Junshuang
    Peng, Jiangzhou
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (01) : 828 - 835
  • [37] The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
    Browne, C.
    Ayoube, T.
    Samarasinghe, N.
    Hussaini, K.
    Warner, A.
    Black, M.
    Palma, D. A.
    Raphael, J.
    Kuruvilla, M. S.
    Blanchette, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1065 - S1065
  • [38] Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
    Gao, F.
    Zhao, Y.
    Li, X.
    Li, Y.
    Ma, T.
    Li, Q.
    Tang, X.
    Han, X.
    Yi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069
  • [39] Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study
    Pons-Tostivint, Elvire
    Ezzedine, Remy
    Goronflot, Thomas
    Crequit, Perrine
    Chatellier, Thierry
    Raimbourg, Judith
    Bennouna, Jaafar
    Leprieur, Etienne Giroux
    Porte, Marie
    LUNG CANCER, 2024, 194
  • [40] Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
    O'Byrne, K. J.
    Zhang, Y.
    Ouyang, J.
    Chou, W-C.
    Chou, C-H.
    Wu, J.
    Adelakun, O.
    Hollmann, T.
    Zeng, J. A.
    Corrella, L.
    Metzler, M.
    Green, C.
    Sarmiento, R.
    Lees, E.
    Liu, Y.
    Ojalvo, L.
    Wu, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1069 - S1070
12345